



500 Linden Oaks
Rochester, New York 14625

FOR IMMEDIATE RELEASE

INVESTOR RELATIONS CONTACT:

Tim Ryan
Trout Group Investor Relations
(646)378-2924
tryan@troutgroup.com

COMPANY CONTACT:

Molly Henderson
Chief Financial Officer
(585)249-6231

VIRTUALSCOPICS 2007 EARNINGS CONFERENCE CALL

Scheduled for February 28, 2008 at 11:00am

ROCHESTER, N.Y. – February 19, 2008 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of image-based solutions to the pharmaceutical, medical device and biotech industries, announced today that on February 27, 2008, after the market closes, it will release its 2007 fourth quarter and year-end results for the period ended December 31, 2007. The company will host a conference call to discuss these results on Thursday, February 28, 2008 at 11:00 a.m. EST.

VirtualScopics' President & Chief Executive Officer, Jeff Markin, and Chief Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the fourth quarter and year end 2007, along with a 2008 outlook, during the conference call.

Interested participants should call 877-407-0778 when calling within the United States or 201-689-8565 when calling internationally. There will be a playback available until March 28, 2008. To listen to the playback, please call 877-660-6853 when calling within the United States or 201-612-7415 when calling internationally. For the replay, please use account number: 286, conference ID number: 275527.

This call is being Web cast by Vcall and can be accessed at www.virtualscopics.com. The Web cast will be available for 30 days after the call.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

#####

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.